Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels
Executive Summary
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
You may also be interested in...
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
GDUFA III: US FDA Says Generic Drug Supplement Volume Could Require More Resources
Will the growing workload cause GDUFA fees to increase or prompt other changes?